Search Result

Results for "

pan inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AAK1 (1) Akt (30) Aldose Reductase (1) AMPK (5) Amyloid-β (2) Androgen Receptor (3) Antibiotic (7) Apoptosis (71) ATM/ATR (1) Aurora Kinase (2) Autophagy (19) Bacterial (12) Bcl-2 Family (10) Bcr-Abl (4) Beta-lactamase (4) Bombesin Receptor (1) Btk (2) c-Fms (1) c-Kit (2) c-Myc (2) Calcium Channel (2) Caspase (22) CD74 (1) CDK (8) COX (1) Cyclin G-associated Kinase (GAK) (1) Cyclophilin (2) Cytochrome P450 (4) Dengue Virus (5) Deubiquitinase (1) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (8) Drug Derivative (1) Drug Intermediate (1) Drug Isomer (1) Drug Metabolite (1) DYRK (1) E-Selectin (1) E1/E2/E3 Enzyme (1) Early 2 Factor (E2F) (1) EGFR (19) Endonuclease (1) Epigenetic Reader Domain (16) ERK (10) Estrogen Receptor/ERR (1) Fc Receptor (FcR) (1) FGFR (10) Filovirus (3) Flavivirus (6) FLT3 (3) G protein-coupled Bile Acid Receptor 1 (1) GABA Receptor (1) GLUT (2) Glutathione Peroxidase (1) Glycosidase (1) GSK-3 (3) HBV (1) HCN Channel (1) HCV (12) HCV Protease (3) HDAC (18) HIF/HIF Prolyl-Hydroxylase (6) Hippo (MST) (1) Histone Acetyltransferase (1) Histone Demethylase (9) Histone Methyltransferase (1) HIV (2) HPV (3) HRASLS (1) HSP (1) IAP (3) IKK (3) Influenza Virus (7) Integrin (1) Interleukin Related (5) IRAK (3) Isocitrate Dehydrogenase (IDH) (2) Isotope-Labeled Compounds (5) JAK (11) JNK (1) Kallikrein (1) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (2) LPL Receptor (2) LRRK2 (3) MAP3K (2) MARCKS (1) MDM-2/p53 (4) MEK (3) MHC (1) Mitochondrial Metabolism (1) Mitophagy (3) MMP (2) Molecular Glues (1) Monoamine Oxidase (2) mTOR (17) MyD88 (1) NADPH Oxidase (2) Necroptosis (3) NF-κB (6) Notch (3) NTPDase (3) Nuclear Factor of activated T Cells (NFAT) (1) Nuclear Hormone Receptor 4A/NR4A (1) Organoid (4) Orphan GPCR (1) Oxidative Phosphorylation (1) P-glycoprotein (3) P-selectin (1) p38 MAPK (8) PAK (2) PANoptosis (2) Parasite (4) PARP (1) PDGFR (1) PDHK (2) PDI (2) PERK (3) Phosphatase (6) Phosphodiesterase (PDE) (4) Phospholipase (1) PI3K (33) Pim (15) PIN1 (1) PKC (8) PKD (6) Polo-like Kinase (PLK) (1) PPAR (2) PROTAC Linkers (1) PROTACs (6) Proteasome (1) Protein Arginine Deiminase (1) Pyroptosis (2) Raf (22) Ras (44) Reactive Oxygen Species (ROS) (4) Reference Standards (32) Ribosomal S6 Kinase (RSK) (1) RIP kinase (1) ROCK (2) Salt-inducible Kinase (SIK) (2) SARS-CoV (13) Ser/Thr Protease (1) SHP2 (2) Sirtuin (2) Src (2) SRPK (1) STAT (6) TAM Receptor (2) TGF-β Receptor (1) Tie (1) TNF Receptor (6) Toll-like Receptor (TLR) (1) Topoisomerase (3) Trk Receptor (9) VEGFR (7) Virus Protease (6) WNK Kinase (1) YAP (7) YB-1 (1) YTHDF (1) γ-secretase (1)
By Research Areas:	Cancer (321) Cardiovascular Disease (12) Endocrinology (2) Infection (66) Inflammation/Immunology (67) Metabolic Disease (16) Neurological Disease (24)
Click Chemistry:	PROTAC Synthesis (1) Alkynes (5)

419

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15431

Capivasertib 80+ Cited Publications AZD5363	Akt Autophagy	Cancer
Capivasertib (AZD5363) is an orally active and potent *pan-AKT* kinase inhibitor with IC₅₀ of 3, 7 and 7 nM for Akt1,Akt2 and Akt3, respectively.

HY-10396

Emricasan 50+ Cited Publications PF 03491390; IDN-6556	Caspase Flavivirus	Infection Neurological Disease Cancer
Emricasan (PF 03491390) is an orally active and irreversible *pan-caspase* inhibitor. Emricasan inhibits Zika virus (ZIKV)-induced increases in caspase-3 activity and protected human cortical neural progenitors .

HY-13689

Go 6983 80+ Cited Publications Gö 6983; Goe 6983	PKC	Cancer
Go 6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ, PKCδ and PKCζ with IC₅₀ of 7 nM, 7 nM, 6 nM, 10 nM and 60 nM, respectively.

HY-15246

Tovorafenib 5+ Cited Publications TAK-580; MLN 2480; BIIB-024	Raf	Cancer
Tovorafenib (TAK-580, MLN 2480) is an orally active and selective inhibitor of *pan-Raf* kinase. Tovorafenib can be used for the study of glioma .

HY-12558

LY3009120 10+ Cited Publications DP-4978	Raf Autophagy	Cancer
LY3009120 (DP-4978) is a pan RAF inhibitor which inhibits BRAF ^V600E, BRAF ^WT and CRAF ^WT with IC₅₀s of 5.8, 9.1 and 15 nM, respectively.

HY-15965

Uprosertib 15+ Cited Publications GSK2141795	Akt	Cancer
Uprosertib (GSK2141795) is a potent and selective *pan-Akt* inhibitor with IC₅₀ values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.

HY-10082

Triapine 5+ Cited Publications 3-AP; pan-811; OCX191	DNA/RNA Synthesis	Cancer
Triapine (3-AP; PAN-811) is a potent inhibitor of the M2 subunit of ribonucleotide reductase (RR), and is a potent radiosensitizer.

HY-13452

CID-1067700 10+ Cited Publications ML282	Ras	Inflammation/Immunology
CID-1067700 (ML282) is a pan GTPase inhibitor, and competitively inhibits Ras-related in brain 7 (Rab7) with a K_i of 13 nM.

HY-13253

AMG 900 4 Publications Verification	Aurora Kinase	Cancer
AMG 900 is a potent and highly selective *pan-Aurora* kinases inhibitor with IC₅₀ of 5 nM, 4 nM and 1 nM for Aurora A, B and C, respectively.

HY-13304

LY2874455 3 Publications Verification	FGFR	Cancer
LY2874455 is a *pan-FGFR* inhibitor with IC₅₀s of 2.8, 2.6, 6.4, 6 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively.

HY-138543

NITD-688 EYU-688	Flavivirus Dengue Virus Virus Protease	Infection
NITD-688 is an orally active pan-serotype inhibitor of the dengue virus NS4B protein. NITD-688 can be used in the research of dengue virus (DENV) .

HY-158409

Pan-RAS-IN-2	Molecular Glues Ras Cyclophilin PERK	Cancer
Pan-rasin-2 (compound 6A) is an orally active molecular glues that targets RAS. Pan-RAS-IN-2 inhibits pERK (IC₅₀ in AsPC-1 cells: 0.3 nM). Pan-rasin-2 has significant inhibitory activity on cell proliferation of RAS mutant cell lines. Pan-rasin-2 can form ternary complexes with cyclophilin A (CYPA) and RAS (ON) proteins and the formation of ternary complexes can block the binding of RAF downstream of RAS, which has anti-tumor (such as colorectal cancer, pancreatic cancer) effects .

HY-162960

pan-KRAS-IN-18	Ras	Cancer
pan-KRAS-IN-18 is a panKRAS inhibitor that inhibits KRAS WT and KRAS G12V with IC₅₀s of 29 and 9 nM, respectively. pan-KRAS-IN-18 exhibits antiproliferative activity in KRAS-mutant cell lines. pan-KRAS-IN-18 can be used for lung cancer research .

HY-16667

HLM006474 5+ Cited Publications	Early 2 Factor (E2F)	Cancer
HLM006474 is a pan E2F inhibitor, which inhibits E2F4 DNA-binding with an IC₅₀ of 29.8 μM in A375 cells.

HY-134957

VT107 5+ Cited Publications	YAP	Cancer
VT-107, as an analogous to VT104, is an orally active and potent *pan-TEAD* auto-palmitoylation inhibitor. VT-107 can be used for the research of cancer .

HY-101295

Pan-RAS-IN-1 5+ Cited Publications	Ras	Cancer
Pan-RAS-IN-1 is a *pan-Ras* inhibitor that disrupts the interaction of Ras proteins and their effectors.

HY-148098

Pan KRas-IN-1 1 Publications Verification	Ras	Cancer
Pan KRas-IN-1 is a pan KRas inhibitor, can be used for agent resistance in cancer developed with KRas G12C inhibitors .

HY-10425

Rizavasertib 10+ Cited Publications A-443654	Akt	Cancer
A-443654 is a *pan-Akt* inhibitor and has equal potency against Akt1, Akt2, or Akt3 within cells (K_i=160 pM) .

HY-100020

BAY-1436032 3 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.

HY-15767

TAK-632 4 Publications Verification	Raf Aurora Kinase	Cancer
TAK-632 is a potent *pan-RAF* inhibitor with IC₅₀ of 1.4, 2.4 and 8.3 nM for CRAF, BRAF ^V600E, BRAF ^WT, respectively.

HY-101023

MK-8617 3 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
MK-8617 is an orally active pan-inhibitor of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) with an IC₅₀ of 1 nM for PHD2.

HY-11004

AZ 628 10+ Cited Publications	Raf Apoptosis	Cancer
AZ 628 is a *pan-Raf* kinase inhibitor with IC₅₀s of 105, 34 and 29 nM for B-Raf, B-RafV600E, and c-Raf-1, respectively.

HY-139535

Luxeptinib 1 Publications Verification CG-806	FLT3 Btk Apoptosis	Cancer
Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent *pan-FLT3/pan-BTK* inhibitor. Luxeptinib induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells .

HY-112802

AZD3229	c-Kit	Cancer
AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. AZD3229 inhibits c-KIT with an IC₅₀ value of 223.3 nM .

HY-101780

Tinostamustine 4 Publications Verification EDO-S101; NL-101	HDAC	Cancer
Tinostamustine (EDO-S101) is a pan HDAC inhibitor; inhibits HDAC6, HDAC1, HDAC2 and HDAC3 with IC₅₀ values of 6 nM, 9 nM, 9 nM and 25 nM, respectively .

HY-15186A

Ipatasertib dihydrochloride 55+ Cited Publications GDC-0068 dihydrochloride; RG-7440 dihydrochloride	Organoid Akt	Cancer
Ipatasertib dihydrochloride (GDC-0068 dihydrochloride) is a highly selective and ATP-competitive *pan-Akt* inhibitor with IC₅₀s of 5, 18 and 8 nM for Akt1, Akt2 and Akt3, respectively.

HY-10530

Varlitinib 2 Publications Verification ASLAN001; ARRY-334543	EGFR	Cancer
Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC₅₀s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively .

HY-123900

AZ12799734	TGF-β Receptor	Cardiovascular Disease
AZ12799734 is a selective, orally active TGFBR1 kinase inhibitor with an IC₅₀ of 47 nM. AZ12799734 is also a pan BMP and TGFβ inhibitor .

HY-12846

CCT196969	Raf	Cancer
CCT196969 is a pan-Raf inhibitor, which inhibits B-Raf, BRaf ^V600E and CRAF with IC₅₀s of 0.1, 0.04, and 0.01 μM, respectively.

HY-N6794

10Z-Hymenialdisine (Z)-Hymenialdisine; Hymenialdisine	AMPK VEGFR PDGFR	Cancer
10Z-Hymenialdisine ((Z)-Hymenialdisine) is a natural bioactive pyrrole alkaloid. 10Z-Hymenialdisine is a pan kinase inhibitor, and has anticancer activities .

HY-12988

C527 1 Publications Verification	Deubiquitinase	Cancer
C527 is a is a pan DUB enzyme inhibitor, with a high potency for the USP1/UAF1 complex (IC₅₀=0.88 μM).

HY-118263

Dacomitinib hydrate 25+ Cited Publications PF-00299804 hydrate; PF-299804 hydrate	EGFR	Cancer
Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC) .

HY-12518

OF-1 4 Publications Verification	Epigenetic Reader Domain	Cancer
OF-1, a chemical probe, is a potent pan-BRPF bromodomain (BRD) inhibitor, with IC₅₀ values of 270 nM, 1.2 μM for TRIM24 and BRPF1B, respectively .

HY-156529

pan-KRAS-IN-2	Ras	Cancer
pan-KRAS-IN-2 (Compound 6) is a pan-inhibitor with IC₅₀s ≤ 10 nM for KRAS WT and mutants (G12D, G12C, G12V, G12S, G12A and Q61H); and an IC₅₀ > 10 μM for KRAS G13D. pan-KRAS-IN-2 can be used to study various KRAS-mediated cancers, such as pancreatic cancer and colorectal cancer .

HY-107549

KD 5170	HDAC	Cancer
KD 5170 is a pan inhibitor of histone deacetylases (HDACs) and exhibits broad spectrum antitumor activity in vitro and in vivo .

HY-163455

pan-HCN-IN-1	HCN Channel	Neurological Disease
pan-HCN-IN-1 (Compound J&J12e) is an inhibitor for hyperpolarization-activated and cyclic-nucleotide-gated 1 (HCN1) ion channel, with IC₅₀ of 58 nM. pan-HCN-IN-1 reduces the voltage sag response and enhances EPSP summation in ex vivo rats brain slices .

HY-176707

GSK2181306A	Parasite	Infection
GSK2181306A is a pan-FIKK inhibitor with an EC₅₀ value of 0.16 μM for parasite growth inhibition. GSK2181306A can be used to study Plasmodium infection .

HY-12419

BMS-983970	Notch	Cancer
BMS-983970 is an oral pan-Notch inhibitor for the treatment of multiplecancers .

HY-159953

IRAK1/4/pan-FLT3 Kinase-IN-1	IRAK FLT3	Inflammation/Immunology Cancer
IRAK1/4/pan-FLT3 Kinase-IN-1 is an orally active, potent and selective *IRAK/pan-FLT3* kinase inhibitor with IC₅₀s of 5 nM, 0.6 nM and <0.5 nM against IRAK1, IRAK4 and FLT3, respectively. IRAK1/4/pan-FLT3 Kinase-IN-1 can be used for research on AML .

HY-12305A

(R)-Q-VD-OPh (R)-QVD-OPH; (R)-Quinoline-Val-Asp-Difluorophenoxymethylketone	Apoptosis	Cancer
(R)-Q-VD-OPh ((R)-QVD-OPH) is the less active enantiomer of Q-VD-OPha. Q-VD-OPha is an irreversible pan-caspase inhibitor with potent antiapoptotic properties.

HY-100696

PNZ5	Epigenetic Reader Domain	Cancer
PNZ5 is a potent and isoxazole-based *pan-BET* inhibitor with high selectivity and potency similar to the well-established (+)-JQ1, with a K_D of 5.43 nM for BRD4(1) .

HY-136567

TBAP-001	Raf	Cancer
TBAP-001 (Synthesis 13), extracted from patent WO2015075483A1, is a pan-RAF kinase inhibitor, with an IC₅₀ of 62 nM in BRAF V600E kinase assay .

HY-163299

pan-KRAS-IN-5 1 Publications Verification	Ras Apoptosis PI3K Akt p38 MAPK	Cancer
pan-KRAS-IN-5 is a pan-KRAS translation inhibitor by targeting 5′-UTR RNA G-quadruplexes (rG4s). pan-KRAS-IN-5 strongly binds to and stabilizes KRAS rG4s, inhibits KRAS translation, and blocks the MAPK and PI3K-AKT pathways. pan-KRAS-IN-5 induces cell cycle arrest, prompts apoptosis in KRAS-driven cancer cells. pan-KRAS-IN-5 inhibits tumor growth and KRAS expression in KRAS-mutant xenograft. KRAS-IN-5 can be used for KRAS-driven cancer research .

HY-101783

GNE-955	Pim	Cancer
GNE-955 is a potent and orally active pan Pim kinase inhibitor with K_is of 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively.

HY-156555

pan-KRAS-IN-3	Ras	Cancer
pan-KRAS-IN-3 (Example 84) is a pan-KRAS inhibitor. pan-KRAS-IN-3 can be used for research of cancers . pan-KRAS-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-142656

PIM-IN-1	Pim	Cancer
PIM-IN-1 is a pan-PIM kinase inhibitor (KG-1, EC₅₀ = 61 nM; pS6, EC₅₀ = 71 nM).

HY-111823

VH032 thiol VHL ligand 6	Ligands for E3 Ligase	Cancer
VH032 thiol (VHL ligand 6) is a VHL ligand, which binds to pan-BET inhibitor JQ1 via a linker to form PROTAC .

HY-163489

pan-KRAS-IN-15	Ras	Cancer
pan-KRAS-IN-15 (compound 58) is a pan-KRAS inhibitor. pan-KRAS-IN-15 can be used in pancreatic cancer research .

HY-164802

Pan-RAS-IN-7	Ras	Cancer
Pan-RAS-IN-7 (Compound D101) is a pan RAS inhibitor that can be used for the synthesis of ADCs. Pan-RAS-IN-7 can be utilized in cancer research .

HY-162439

pan-KRAS-IN-6	Ras	Cancer
pan-KRAS-IN-6 (compound 12) is a potent pan KRAS inhibitor with IC₅₀ values of 9.79 nM (Kras G12D) and 6.03 nM (Kras G12V) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-10985

Marizomib Maximum Cited Publications 17 Publications Verification Salinosporamide A; NPI-0052	Marine natural products Marine microorganism Source Classification	Proteasome
Marizomib (Salinosporamide A) is a second-generation, irreversible, brain-penetrant, *pan-proteasome* inhibitor. Marizomib inhibits the CT-L (β5), CT-T-laspase-like (C-L, β1) and trypsin-like (T-L, β2) activities of the 20S proteasome (IC₅₀=3.5, 28, and 430 nM, respectively) .

HY-W016420

Fosfomycin sodium 10+ Cited Publications MK-0955 sodium	Infection Structural Classification Natural Products Microorganisms Classification of Application Fields Disease Research Fields Source Classification	Bacterial Antibiotic
Fosfomycin (MK-0955) sodium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin sodium shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria .

HY-124586

Streptonigrin 1 Publications Verification Bruneomycin	Infection Quinones Alkaloids Monophenols Microorganisms Classification of Application Fields Phenols Pyridine Alkaloids Benzene Quinones Disease Research Fields Source Classification Cancer	Antibiotic Protein Arginine Deiminase E1/E2/E3 Enzyme HIF/HIF Prolyl-Hydroxylase MDM-2/p53 Apoptosis
Streptonigrin (Bruneomycin) is an orally active antibiotic and *pan-PAD* inhibitor, inhibiting PAD1, PAD2, PAD3 and PAD4 with IC₅₀ of 48.3 μM, 26.1 μM, 0.43 μM and 2.5 μM, respectively. Streptonigrin inhibits SENP1 (IC₅₀ of 0.518 μM) and reduces HIF1α. Streptonigrin increases p53 and Apoptosis. Streptonigrin shows antiviral activity against Rauscher murine leukemia virus. Streptonigrin has immunosuppressive effects. Streptonigrin has antitumor activity against osteosarcoma .

HY-N0234

Bavachinin 5+ Cited Publications 7-O-Methylbavachin; Bavachinin A	Monophenols Flavonoids Classification of Application Fields Leguminosae Flavonones Phenols Psoralea corylifolia L. Plants Inflammation/Immunology Disease Research Fields Source Classification	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-N6794

10Z-Hymenialdisine (Z)-Hymenialdisine; Hymenialdisine	Alkaloids Pyrrole Alkaloids Animals Classification of Application Fields Marine natural products Sponge Disease Research Fields Biological Pesticide Research Source Classification Cancer Agricultural Research	AMPK VEGFR PDGFR
10Z-Hymenialdisine ((Z)-Hymenialdisine) is a natural bioactive pyrrole alkaloid. 10Z-Hymenialdisine is a pan kinase inhibitor, and has anticancer activities .

HY-N0475

Triptophenolide Hypolide; (+)-Triptophenolide	Structural Classification Monophenols Classification of Application Fields Terpenoids Celastraceae Other Diseases Phenols Diterpenoids Tripterygium wilfordii Hook. f. Plants Disease Research Fields Source Classification	Androgen Receptor Pyroptosis Caspase Bcl-2 Family Apoptosis
Triptophenolide (Hypolide) is a colorless crystal isolated from the ethyl acetate extract of Tripterygium wilfordii. Triptophenolide is an orally active pan‑antagonist of the androgen receptor (AR) with an IC₅₀ of 467 nM against human wild‑type AR. Triptophenolide reduces AR expression, inhibits AR nuclear translocation, downregulates prostate‑specific antigen mRNA levels, and suppresses the growth of AR‑positive prostate cancer cells. Triptophenolide shows anti-tumor effects against breast cancer by inhibiting cell proliferation and migration, inducing G1-phase arrest and apoptosis, repressing xenograft tumor growth. Triptophenolide inhibits pyroptosis, alleviates tissue inflammation, and ameliorates synovial injury. Triptophenolide can be used for the study of prostate cancer, rheumatoid arthritis and breast cancer .

HY-167884

PF-1367550	Alkaloids Aristolochia debilis Sieb. et Zucc. Plants Aristolochiaceae Source Classification	JAK
PF-1367550 is a pan-JAK inhibitor. PF-1367550 can decrease the levels of release of CXCL9, CXCL10 and CXCL11 from primary airway epithelial cells .

HY-N15315

Triptriolide	Triterpenes Terpenoids Celastraceae Tripterygium wilfordii Hook. f. Plants Source Classification	Apoptosis MAP3K NF-κB
Triptriolide inhibits Puromycin aminonucleoside PAN (HY-15695)-induced apoptosis in mouse podocytes through regulation of Bcl-2 family proteins and inhibition of Caspase-3. Triptriolide promotes the cell survival, protects and restores the podocyte function through activation of TAK1-NF-κB signaling pathway and upregulation of podocin .

HY-N0234R

Bavachinin (Standard) 7-O-Methylbavachin (Standard); Bavachinin A (Standard)	Structural Classification Monophenols Flavonoids Leguminosae Flavonones Phenols Psoralea corylifolia L. Plants Source Classification	Amyloid-β Reference Standards PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-N0475R

Triptophenolide (Standard) Hypolide (Standard); (+)-Triptophenolide (Standard)	Structural Classification Monophenols Terpenoids Celastraceae Phenols Diterpenoids Tripterygium wilfordii Hook. f. Plants Source Classification	Reference Standards Androgen Receptor Pyroptosis Caspase Bcl-2 Family Apoptosis
Triptophenolide (Standard) (Hypolide) is the analytical standard of Triptophenolide (HY-N0475). This product is intended for research and analytical applications. Triptophenolide is a colorless crystal isolated from the ethyl acetate extract of Tripterygium wilfordii. Triptophenolide is an orally active pan‑antagonist of the androgen receptor (AR) with an IC₅₀ of 467 nM against human wild‑type AR. Triptophenolide reduces AR expression, inhibits AR nuclear translocation, downregulates prostate‑specific antigen mRNA levels, and suppresses the growth of AR‑positive prostate cancer cells. Triptophenolide shows anti-tumor effects against breast cancer by inhibiting cell proliferation and migration, inducing G1-phase arrest and apoptosis, repressing xenograft tumor growth. Triptophenolide inhibits pyroptosis, alleviates tissue inflammation, and ameliorates synovial injury. Triptophenolide can be used for the study of prostate cancer, rheumatoid arthritis and breast cancer .

Cat. No.	Product Name	Chemical Structure

HY-176785S

MCB-294

MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with K_ds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC₅₀s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRAS ^G12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer .

HY-12530S1

Velpatasvir-d3
Velpatasvir-d₃ (GS-5816-d₃) is deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-B1075AS

(Rac)-Fosfomycin (benzylamine)-13C3

(Rac)-Fosfomycin (benzylamine)- ¹³C₃ is the ¹³C labeled Fosfomycin . Fosfomycin (MK-0955) is a broad-spectrum antibiotic. Fosfomycin can cross blood-brain barrier penetrating, and irreversibly inhibits an early stage in cell wall synthesis. Fosfomycin shows anti-bacteria activity for a range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria .

HY-131905S

BMS-986144
BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC₅₀s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection .

HY-10082S1

Triapine-d3
Triapine-d₃ (3-AP-d₃) is deuterium labeled Triapine. Triapine (3-AP; PAN-811) is a potent inhibitor of the M2 subunit of ribonucleotide reductase (RR), and is a potent radiosensitizer.

HY-124592

BMT-052
BMT-052 is a pan-genotypic hepatitis C (HCV) NS5B polymerase primer grip inhibitor .

HY-W749691

(S)-Velpatasvir-13c,d3
(S)-Velpatasvir- ¹³C,d₃ ((S)-GS-5816- ¹³C,d₃) is ¹³C labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM ^.

HY-12530S3

Velpatasvir-13C,d3
Velpatasvir- ¹³C,d₃ (GS-5816- ¹³C,d₃) is ¹³C and deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12305G

Q-VD-OPh	Caspase HIV	Infection Cancer
Q-VD-OPh (GMP) is Q-VD-OPh (HY-12305) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Q-VD-OPh is an irreversible *pan-caspase* inhibitor with potent antiapoptotic properties; inhibits caspase 7 with an IC₅₀ of 48 nM and 25-400 nM for other caspases including caspase 1, 3, 8, 9, 10, and 12. Q-VD-OPh can inhibits HIV infection. Q-VD-OPh is able to cross the blood-brain barrier.

HY-16658BG

Z-VAD-FMK	Caspase Apoptosis	Cancer
Z-VAD-FMK is a *pan-caspase* inhibitor and also an ICE-like protease inhibitor, which inhibits apoptosis by preventing the processing of CPP32 to its active form. Z-VAD-FMK sensitivity varies primarily due to differential expression of receptor-interacting protein 1 (RIP1). Z-VAD-FMK limits the cryopreservation-induced apoptosis by reducing caspase-3 activity of in vitro produced bovine embryos. Z-VAD-FMK is immunosuppressive in vitro and inhibits T cell proliferation without blocking the processing of caspase-8 and caspase-3. Z-VAD-FMK leads to a decrease in intracellular glutathione (GSH) with a concomitant increase in reactive oxygen species (ROS) levels in activated T cells. Z-VAD-FMK is due to oxidative stress via the depletion of GSH. Z-VAD-FMK can be used for the study of acute pancreatitis .

HY-10966G

SB-590885	Raf Apoptosis	Cardiovascular Disease Cancer
SB-590885 GMP is SB-590885 (HY-10966) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks